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The widely expressed protein Fas is a member of the tumour
necrosis factor receptor family which can trigger apoptosis1.
However, Fas surface expression does not necessarily render
cells susceptible to Fas ligand-induced death signals1,2, indicating
that inhibitors of the apoptosis-signalling pathway must exist.
Here we report the characterization of an inhibitor of apoptosis,
designated FLIP (for FLICE-inhibitory protein), which is predo-
minantly expressed in muscle and lymphoid tissues. The short
form, FLIPS, contains two death effector domains and is structu-
rally related to the viral FLIP inhibitors of apoptosis3, whereas the
long form, FLIPL, contains in addition a caspase-like domain in
which the active-centre cysteine residue is substituted by a
tyrosine residue. FLIPS and FLIPL interact with the adaptor
protein FADD4,5 and the protease FLICE6,7, and potently inhibit
apoptosis induced by all known human death receptors1. FLIPL is
expressed during the early stage of T-cell activation, but dis-
appears when T cells become susceptible to Fas ligand-mediated
apoptosis. High levels of FLIPL protein are also detectable in
melanoma cell lines and malignant melanoma tumours. Thus
FLIP may be implicated in tissue homeostasis as an important
regulator of apoptosis.
We have recently described a family of six viral inhibitors (v-
FLIPs) that are present in several g-herpesviruses and molluscipox-
virus, and which contain two death effector domains (DEDs)3.
These inhibitors block the early signalling events of the death
receptors Fas, TRAMP (wsl/DR-3/Apo-3), TRAIL-R (DR-4) and
tumour necrosis factor receptor 1 (TNF-R1) (refs 1, 3, 8). v-FLIPs
bind to the DED of FADD (MORT-1) and interfere with the FADD–
FLICE (Caspase 8/MACH/Mch-5) interaction, thereby inhibiting
the recruitment and activation of FLICE by Fas3. Some v-FLIPs may
also exert their inhibitory effect by binding directly to the DEDs of
FLICE8. Because many viral genes are adopted host genes, we
considered the possibility that cellular homologues of the v-FLIPs
may exist. We screened public databases with a generalized profile9
constructed from the six known members of the v-FLIP family and
identified a partial human sequence with highly significant homology
(P , 10 2 10) to v-FLIPs (Fig. 1a). When the corresponding
expressed sequence tag (EST) clone was used to screen a cDNA
library from activated human peripheral blood leukocytes, we
isolated several cDNA clones encoding a protein with an overall
structural organization similar to the v-FLIPs, which we designated
FLIPS. This protein consists of two DEDs, followed by a carboxy-
terminal extension of approximately 50 amino acids. An alterna-
tively spliced cDNA coding for a longer form of FLIP, designated
FLIPL, was also isolated. Within this protein the two DEDs are
followed at the C terminus by a caspase-like domain, giving rise to a
molecule structurally similar to FLICE (Fig. 1a). The gene for FLIP
co-localizes with the FLICE homologue Mch4 (caspase 10)10 to the
chromosome 2q33 (ref. 11), suggesting that the genes coding for
Mch4, FLIP and probably FLICE arose by gene duplication. How-
ever, the amino-acid position corresponding to the active-site
cysteine of FLICE is substituted by a Tyr residue in FLIPL. The
active-site cysteine was absent in all human FLIPL-encoding cDNA
clones analysed (four clones), as well as in mouse FLIPL, which had
been isolated by screening a murine heart muscle cDNA library (Fig.
1a). Moreover, of the two other residues involved in catalysis12,13 and
conserved in members of the caspase family, only the Gly residue is
conserved (Fig. 1a); the His residue is substituted by an Arg (human
FLIPL) or a Leu residue (mouse FLIPL). FLIPL was therefore
expected to be proteolytically inactive, similar to the FLICE-1
(ref. 7) and FLICE-2 (ref. 14) mutants in which the catalytic cysteine
residue had been replaced. Indeed, in contrast to FLICE, the caspase
region of FLIPL was unable to cleave two caspase-specific peptide
substrates7 (Fig. 1b). However, we cannot completely exclude the
possibility that the caspase-like region of FLIPL can act on different
peptides.
Northern blots of human tissues revealed that four main FLIP
RNA species exist which are predominantly expressed in heart,
skeletal muscle and peripheral blood leukocytes (PBLs) (Fig. 1c).
The shortest transcript (1.1–1.3 kilobases) probably corresponds to
FLIPS, as it was not detected with an RNA probe uniquely spanning
the caspase region of FLIPL. Three longer, less abundantly expressed
transcripts reacted with both the caspase and the DED probes, and
presumably corresponded to FLIPL.
Triggering of Fas results in the incorporation of v-FLIPs into the
death-inducing signalling complex (DISC)3,15. To assess whether
cellular FLIP was functionally similar to v-FLIP, we analysed its
interaction with FADD, which connects Fas with FLICE during
death signal transduction6,7. Indeed, both human FLIPL (relative
molecular mass (Mr) of ,55K) and FLIPS (Mr ,28K) associated
strongly with FADD (Fig. 2a) when coexpressed in 293T cells. The
FLIPL–FADD interaction was mediated by the DEDs of FLIPL, as
the caspase-like region of FLIPL (FLIPc) displayed no affinity for
FADD. In cells transfected with expression vectors for FLIPS, FLIPL,
FADD and the cytoplasmic portion of Fas, a stable Fas–FADD–
FLIPL (or FLIPS) complex was formed, indicating that both forms of
FLIP can incorporate into the DISC of Fas.
Current evidence suggests that precursor caspases are activated
and autoprocessed as a dimeric complex, ultimately resulting in a
stable (p10/p20)2 complex
12,13,16. Correspondingly FLICE over-
expression in 293T cells resulted in the formation of dimers or
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higher oligomers of FLICE (the experimental conditions do not
allow the distinction between these two possibilities) (Fig. 2b). We
therefore anticipated that the FLICE-like FLIPL would also form
homodimers. However, FLIPL dimers (or oligomers) were not
detectable (Fig. 2c). In contrast, FLIPL interacted with FLICE
(Fig. 2d), indicating that heterodimers can be formed between
functional (FLICE) and non-functional (FLIPL) caspases. The
presence of FLICE in immunoprecipitates of FLIPS and of FLIPc
(the caspase-like region of FLIPL) revealed that both the N-terminal
DEDs, as well as the C-terminal caspase-like region of FLIPL,
contribute to the interaction with FLICE (Fig. 2d).
Overexpression of FLIPL in 293T cells in the absence of z-VAD-
fmk (a caspase inhibitor which had been included in the experi-
ments described above) resulted in the appearance of two molecular
species. One of these corresponds to the expected molecular size of
full-length FLIPL (Mr,55K), and the second is a C-terminally
truncated form of FLIPL (Mr,43K; FLIP43), which arises from
cleavage after Asp 376 of FLIPL (data not shown) corresponding to
the p17–p12 boundary in other related caspase members (Figs. 1a,
2e). Initial processing of FLICE during Fas-mediated activation
occurs at the corresponding site17. Precursor FLICE is a natural
substrate of active FLICE6,17, and it is therefore likely that the FLICE-
like FLIPL is processed by endogenous FLICEs. Processing of full-
length FLIPL into the 43K form was also observed when Raji B cells,
stably transfected with FLIPL (see below), were treated with soluble
Fas ligand (sFasL) (Fig. 2e). The cleavage of FLIPL is reminiscent of
the cleavage of the viral apoptosis inhibitor p35 (refs 18, 19), which
is an excellent substrate for several caspases, yet its cleavage results in
a tighter binding to the caspases. Similarly, FLIPL cleavage through
receptor-activated FLICE may result in a strong FLIPL–FLICE
interaction, thereby blocking further processing and activation of
FLICE. This model, together with the FLIP interaction data (Fig. 2),
predicts that FLIP is capable of arresting death receptor signals. This
was validated experimentally in 293T cells, where the extensive
cellular death induced by the overexpression of Fas was efficiently
reduced by coexpression of FLIPL (Fig. 3a) and FLIPS (data not
shown). Moreover, coexpression of FLIPS or FLIPL, but not of FLIPc
(the caspase-like domain of FLIPL; see Fig. 1a), protected 293T cells
from apoptosis induced by TRAMP (DR3/wsl/Apo-3)20,23 (Fig. 3b),
indicating that the presence of the DEDs within FLIPL is essential for
Figure 1 a, Amino-acid sequence alignment of human (HS) and mouse (MM) FLIPs, the viral
FLIP (v-FLIP) from equine herpesvirus-2 (EHV2) (GenBank accession no. U20824), FLICE (ref. 6)
and Mch4 (ref.10). The long form of FLIP (FLIPL) contains two DEDs and a caspase-like domain,
linked by a region of ,65 amino acids. The sequence of the alternatively spliced short form of
FLIP (FLIPS) includes the two DEDs. Thus, the first 202 amino acids of the long and the short
form of human FLIPare identical; only the unique C-terminal 19 amino acids of FLIPS are shown
here.A typical splice consensus sequence is foundat the site of divergence between FLIPL and
FLIPS. For each block of aligned sequences, black boxes indicate .50% amino-acid sequence
identity; while grey shading indicates .50% sequence similarity through conservative amino-
acid substitutions. The positions corresponding to the residues of FLICE and Mch4 involved in
catalysis12,13 (His, Gly and Cys) are marked by a star, and the active-centre Cys is boxed. Open
circles indicate caspase residues constituting the binding pocket for the carboxylate chain of
the P1 Asp residue12,13. The boundary of the p17 and p12 subunits of FLICE6,7 and the start of the
caspase region-containing construct of FLIPL (FLIPc) are indicated. b, The caspase homology
region of FLIPL lacks protease activity. Cleavage kinetics of the poly(ADP ribose) polymerase
(PARP)-derived fluorogenic substrate, Ac-DEVD-AMC (50 mM) by the caspase homology
region of FLICE (Ser 217 through the C terminus; filled symbols) and of FLIPL (Ala 233 through
the C terminus; open symbols). Both proteins failed to cleave the fluorogenic substrate Ac-
YVAD-AMC (ICE-cleavage site in the interleukin-1b precursor; data not shown). c, Tissue
distributionof the FLIP transcripts. Northern blots (2 mg poly(A+)RNA per lane) of varioushuman
tissues were probed with antisenseRNA covering the N-terminal sequence of FLIPL containing
the two DEDs (FLIP(N), top) and the C-terminal caspase-like domain (FLIP(C), bottom),
respectively. Arrowheads indicate FLIP transcripts detected only by the FLIP(N) probe (open
arrows) or by both probes (FLIP(N) and FLIP(C), filled arrows). The blots were subsequently
hybridized with a b-actin probe.
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the protective function of FLIPL. FLIPL and FLIPS also protected
293T cells against apoptosis induced by overexpression of the
cytoplasmic domain of TNF-R1 (ref. 24), albeit less efficiently
(Fig. 3c and data not shown). Surprisingly, the transfection of
high concentrations of FLIPL expression vector alone (but not of
FLIPS) led to spontaneous cell death in 293T cells (Fig. 3d), raising
the possibility that expression levels of FLIPL may determine the life
or death of a cell. We therefore stably transfected Raji B and Jurkat T
cell lymphomas with FLIPL or FLIPS (Fig. 3e, f). In all clones
obtained (and melanomas and T cells; see below), FLIP protein
levels were at least 10-fold lower than the levels achieved in FLIP-
expressing 293T cells undergoing apoptosis (Fig. 3e), suggesting
that the extremely high concentration of FLIP observed in trans-
fected 293T cells may not be physiological. The amount of FLIP
protein present in stably transfected lymphocyte clones correlated
well with the relative resistance to sFasL-induced cell death (Fig. 3e,
f). Western blot analyses of FLIPS and FLIPL in cells that showed
equal levels of protection against apoptosis consistently revealed
that FLIPL was a more potent inhibitor of cell death than was FLIPS
(Fig. 3e, f). In the Jurkat clone JFS5, for example, the relative level of
FLIPS protein was higher than the level of FLIPL expressed in Jurkat
clone JFL2 or JFL1. However, only the FLIPL-expressing clones were
protected against sFasL-induced apoptosis (the Fas surface expres-
sion was identical in all FLIP-expressing clones; data not shown). In
contrast, the FLIPS levels of JFS5 were sufficient to partly protect the
clone against sTRAIL-induced apoptosis (Fig. 3e), indicating that,
relative to Fas, the TRAIL-R signalling pathway is more effectively
blocked. In view of the recent observation that TRAIL-R does not
recruit FADD25, this suggests that FLIP may preferentially interact
with an unknown DED-containing protein specifically recruited by
the TRAIL-R or, alternatively, that a second FADD-interacting
TRAIL-R exists. FLIP expression did not modulate apoptosis
triggered by various other stimuli, such as the kinase inhibitor
staurosporine (Fig. 3g), or growth factor withdrawal (data not
shown).
FLIP was able to protect lymphoma cell lines against death
receptor-induced apoptosis, so we investigated whether FLIP was
implicated in the resistance of T lymphocytes against FasL-
mediated apoptosis observed during early stages of activation2. In
accordance with published data2, Fas-expressing human T cells were
resistant to sFasL-induced apoptosis one day after mitogen stimula-
tion despite there being abundant surface-exposed Fas levels,
whereas they became sensitive after an additional 5 days in culture
(Fig. 4a). This transient resistance correlated with FLIP expression
levels (Fig. 4a). At day one, a 55K anti-FLIP-reactive band was
detected at a position identical to that found in FLIPL-transfected,
z-VAD-fmk-treated 293T cells. In FasL-responding T cells activated
for 6 days, the level of expression of FLIP had decreased con-
siderably. An anti-FLIP reactive protein migrating at ,28K
(corresponding to FLIPS) was not detected, despite the presence
of high FLIPS RNA levels in PBLs (see Fig. 1c). These results suggest
that FLIPS expression may be controlled at the post-transcriptional
level. Similar results were obtained with mitogen (concanavalin A)-
activated mouse splenocytes (Fig. 4b). Both the 55K and the
processed 43K forms of FLIPL were present in these cells at day
one of stimulation, whereas FLIPL was no longer detectable in FasL-
sensitive lymphocytes analysed 3 days after stimulation (Fig. 4b).
Thus activation of T cells induces a transient resistance to Fas-
induced apoptotic signals that correlates with increased FLIP
expression. FasL-resistant activated T cells fail to recruit and activate
FLICE26 as would be predicted if FLIPs played a major role in this
protection.
Figure 2 FLIPs interact with FADD and FLICE. a, 293T cells were transiently
transfected with expression vectors encoding Flag-FLIPS, Flag-FLIPL, Flag-FLIPc
(covering the caspase-like region of FLIPL), FADD and the myc-tagged
cytoplasmic domain of Fas. In these and the following experiments, appropriate
quantities of vector alone were added to keep the total amount of transfected
plasmid constant and 25 mM z-VAD-fmk was added to FLIPL transfections (except
in e). Cells were lysed 30h after transfection, and anti-Flag immunoprecipitates
(IP) or total cell extracts were analysed for the presence of FADD, Flag-FLIP or
Myc-Fas by western blotting. b, Western blot analysis of anti-HA-FLICE
immunoprecipitates and cell lysates from 293Tcells, transfected with expression
vectors encoding HA-FLICE and FLICE as indicated. c, Western blot analysis of
anti-Flag immunoprecipitates and cell lysates from 293T cells transiently
transfected with expression vectors encoding Flag-FLIPL and VSV-FLIPL. d,
Anti-Flag-FLIP immunoprecipitates and cell extracts from Flag-FLIPL, Flag-FLIPS,
Flag-FLIPc and HA-FLICE transfected 293T cells were analysed by anti-HA and
anti-Flag western blotting. e, FLIPL processing in sFasL-treated Raji cells. 293T
cells were incubated in the absence (- ) or presence (+) of the caspase inhibitor
z-VAD-fmk. In the absence of the inhibitor, FLIPL (55K) is partly processed to a 43K
fragment (FLIP43) in 293Tcells. A Raji B lymphoma clone stably transfected with N-
terminally VSV-tagged FLIPL (clone RFL12; see Fig. 3f) and the parental clone (Raji
wt) were treated for the indicated times with 1 mgml- 1 of recombinant sFasL. Cells
were lysed and processing of VSV-FLIPL was analysed by anti-VSV western
blotting 1 and 2.5 h after the addition of sFasL. The presence of sFasL leads to
partial processing of FLIPL into a 43K N-terminal fragment. A protein migrating at
,60K is detected nonspecifically. The FLIPL-transfected Raji clone is resistant to
apoptosis (see Fig. 3), whereas more than 90% of parental Raji cells have an
apoptotic phenotype 2.5 h after the addition of sFasL.
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Finally, we investigated whether FLIP is expressed in certain
tumour cell lines that are resistant to death receptor-mediated
apoptosis27. None of the melanoma cell lines tested here or in a
previous report27 respond to sFasL (Fig. 4c), despite the fact that
some cell lines express surface Fas (Fig. 4c, d). In contrast to FasL-
sensitive Jurkat cells, the melanoma cell lines express detectable
levels of the 55K form of FLIPL protein (Fig. 4e) and mRNA
(detected by reverse transcription–polymerase chain reaction
(RT–PCR); data not shown). Furthermore, FLIP was expressed in
metastatic cutaneous melanoma lesions from human patients (five
were examined to date, and all express FLIP) (Fig. 4f; data not
shown). In contrast, no FLIP was detected in melanocytes
surrounding the hair follicle of the skin (Fig. 4f), indicating that
FLIP upregulation probably occurs during tumorigenesis. FLIP
expression may therefore contribute to the resistance to FasL of
melanoma cell lines which express surface Fas.
Death receptor-induced apoptosis is an important event in tissue
homeostasis as exemplified by the accumulation of T cells in Fas-
deficient mice1. Therefore, a tight regulation of the balance between
resistance and susceptibility of cells towards apoptosis is required.
In T cells, this resistance is transient to avoid premature activation-
induced cell death and to allow T cell-mediated help or cytotoxicity.
In contrast, certain tumour cells seem to have lost the capacity to
undergo apoptosis, either as a result of the loss of certain death
receptors or by an impaired signalling pathway. Unlike the Bcl-2
family members which are potent inhibitors of apoptosis induced
by growth factor withdrawal and g-irradiation, FLIP seems to
primarily block apoptosis induced by death receptors. In the
examples analysed here (T cells and melanomas), FLIP expression
correlates with the transient or acquired resistance to apoptosis,
suggesting that FLIP may contribute to the blockade of the death
signalling pathways in these cells. Highest FLIP mRNA levels are
detected in the heart. The administration of anti-Fas antibodies into
mice causes death from liver failure, not heart failure, despite the
Figure 3 FLIPs protect eukaryotic cells from death receptor-induced apoptosis. a,
b, 293T cells were transiently transfected with the indicated amounts of
expression vectors for human Fas (a) or human TRAMP (b), together with
human FLIPL, FLIPS or FLIPc and mock vector to keep the total amount of
transfected DNA constant. Where indicated, 25 mM z-VAD-fmk was added to the
cell culture after transfection. Quantitative analysis of cell death (induced by the
overexpressed death receptors Fas or TRAMP in the absence of ligand) was
done using a histone–DNA complex-release assay (the data shown are
means 6 s:d:, n ¼ 3). In a typical transfection experiment, 60–90% of cells under-
went apoptosis upon transfection with death-receptor expression vectors. c,
293Tcells were transiently transfected with the indicated amounts of an expres-
sion vector for the cytoplasmic portion of TNF-R1 together with FLIPL and
analysed as in a. d, Expression of FLIPL and FLIPS in 293T cells. At high
concentrations, FLIPL causes cell death in the absence of death receptors. e, f,
Cellular extracts of VSV-FLIPL-transfected (FL), VSV-FLIPS-transfected (FS) and
untransfected Jurkat (J) T-cell clones, Raji (R) B-cell clones and 293T cells were
analysed for FLIP expression by anti-VSV western blotting (top). Migration
positions of FLIPS and FLIPL are indicated by open arrowheads. The top right
panel ofe shows a comparisonof VSV-FLIPL expression in transiently transfected
293Tcells (in the absence of z-VAD-fmk) and two stably transfected lymphocyte
clones. The arrow points to a protein detected nonspecifically, demonstrating
equal protein loading. The susceptibility of the FLIP-transfected Jurkat (e) and Raji
(f) clones to FasL-induced apoptosis was determined by incubating the cells for
20 h at 37 8C with recombinant sFasL and subsequent determination of cell
viability using a cell proliferation assay. e, FLIPL and FLIPS expressing Jurkat
clones were incubated with the indicated concentrations of recombinant sTRAIL
for 20 h and cell viability was determined using a cell proliferation assay. At high
concentrations of sFasL and sTRAIL, .95% of the untransfected cells underwent
apoptosis. g, Staurosporine-induced cell death is not inhibited by FLIPs. Clones
were treated with the indicated concentrations of staurosporine for 16h, and cell
viability assayed using a cell proliferation assay.
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presence of high levels of Fas in the latter organ28. Targeted
disruption of the FLIP gene may therefore provide an insight into
the physiological role of FLIP. M
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Methods
Antibodies. Monoclonal antibodies used in immunoprecipitations and
western blotting include: an anti-Flag antibody (Kodak International
Biotechnologies); an anti-FADD antibody directed against amino acids 94–
208 of human FADD (Transduction Laboratories); and antibodies against the
myc epitope (9E10, Sigma), the VSV epitope (P5D4, Sigma) and the HA
epitope (12CA5, from R. Iggo, Lausanne). An antiserum against FLICE
(AL105) was generated using a peptide spanning amino acids 380–414 of
FLICE (QTRYIPDEADFLLGMATVNNCVSYRN), and an antiserum against
human FLIP (AL109) was generated against a peptide spanning amino acids 2–
26 (SAEVIHQVEEALDTDEKEMLFLCRD), synthesized using the multiple
antigen technology29. The antisera were affinity purified on the corresponding
peptides coupled to CNBr-Sepharose 4B (Pharmacia). Antibodies used to
detect Fas surface expression by FACScan analysis included the anti-human Fas
antibody Apo-1-3 (Alexis, Dan Diego) and the anti-mouse Fas antibody Jo2
(Pharmingen).
Expression vectors, cell lines,melanoma and reagents. Expression vectors
for FLIPS, FLIPL and FLIPc (see Fig. 1a) were generated by PCR amplification
and subcloning into PCR-3-derived vectors conferring an N-terminal Flag- or
VSV-tag to the expressed proteins. An expression vector for the VSV-tagged
cytoplasmic domain of the murine tumour necrosis factor receptor (TNF-R1)
was generated by insertion of a PCR fragment corresponding to amino acids
242–454 in frame with an N-terminal VSV epitope into a vector derived from
PCR-3 (Invitrogen). The expression vector for HA-tagged FLICE was a gift
from J. P. Medema and M. E. Peter (Heidelberg, Germany). Recombinant
soluble FasL was from Alexis (San Diego). Additional expression vectors, cell
lines and reagents used in this study have been described previously3,20.
Melanoma cell lines were derived from tumour samples obtained from
melanoma patients by surgical excision27. Metastatic melanomas of patients
were removed by surgery and snap-frozen in liquid nitrogen-cooled isopen-
tane. Sections (10 mm thick) were cut and analysed as previously described27.
Screening of cDNA libraries and northern blot analysis. cDNA clones for
human FLIPS and FLIPL were isolated from a cDNA library of activated PBLs (a
gift of H. Eibel, Freiburg) using a 32P-labelled DNA fragment (random primed
labelling kit, Boehringer) encoding amino acids 1–170 of human FLIPS and
generated from EST clone 309776. A cDNA clone for murine FLIPL was isolated
from a murine heart muscle cDNA library (Stratagene) using the same probe.
Northern blot analysis was performed by using human multiple tissue northern
blots I and II (Clontech #7760-1 and #7759-1) according to the manufacturer’s
instructions. Antisense RNA probes containing the nucleotides corresponding
to amino acids 1–170 (probe FLIP-N), 229–480 (FLIP-C) of FLIPL, and b-actin
were used.
Cell transfection, co-immunoprecipitation and western blotting. Stable
transfections of Jurkat and Raji cells, transient transfection of 293T cells,
immunoprecipitations and western blot analysis were done as previously
described3. Jurkat and Raji clones or 293T cells were checked for expression of
transfected proteins by anti-tag western blot analysis of postnuclear cell lysates
with equivalent protein content.
Figure 4 FLIPL is expressed during T-cell activation and in human malignant
melanoma. a, Western blot analysis of phytohaemaglutinin (PHA)-activated
human Tcells at day 1 and 6 of stimulation using the anti-FLIPAL109 antibody. A
cell extract of FLIPL-transfected (0.3 mg DNA) 293Tcells (in the presence of z-VAD-
fmk) is included as a control, and equal protein loading was verified by Ponceau S
staining of the nitrocellulose blot. The middle panel shows the susceptibility of
day 1 and 6 activated T cells to apoptosis induced by treatment with sFasL
(0.2 mg ml- 1) for 6 h. The percentage of apoptotic cells was determined by the
histone-DNA complex-release assay. All data are given as mean 6 s:d: (n ¼ 3).
FACS analysisof Fas surface expression is shownon the right. Cellswere stained
with anti-Fas followed by an anti-mouse FITC-conjugated secondary antibody
(filled curves) and analysed on a FACScan flow cytometer. Open curves repre-
sent cell staining with FITC-conjugated secondary antibody only. b, Western blot
analysis of concanavalin A-activated mouse splenocytes at day 1 and 3 of
stimulation. The quality of the anti-human FLIP antibody towards mouse FLIP
was tested by comparing anti-FLIP and anti-Flag western blots of a cell extract
from 293T cells transfected with a mouse Flag-FLIPL expression vector in the
absence of z-VAD-fmk.Moreover, in the western blot analysisof Tcells from day1,
10 mgml- 1 of the peptide used for immunization was included as a specificity
control. A band migrating at ,41K is detected nonspecifically and demonstrates
equal protein loading. The middle panel shows the susceptibility of day 1 and 3
activated Tcells to FasL-mediated apoptosis. Fas surface expression (right) was
determined as in a, except that the biotinylated anti-mouse Fas antibody Jo2 in
combination with streptavidin-FITC was used for the detection of the antigen. c,
Melanoma cell lines resist killing by sFasL. Various cell lines were incubated with
recombinant sFasL (1 mg ml- 1) for 6 h. The presence(+) or absence(- ) of surface
Fas was verified by FACS analysis (see Fig. 4d). FasL-sensitive Jurkat cells were
used as control target cells.d, Fas surface expressionon two selected melanoma
cell lines (Me304 and DOR). Cells were stained as in a. e, Expression of FLIPL in
melanoma cell lines. Anti-FLIP western blot analysis of melanoma cell lines
derived from several patients with malignant melanoma. Controls included
293Tcells transfected with a FLIPL expression vector and Jurkat cells. f, Expres-
sion of FLIP (brown) in two examples of human malignant melanoma (Mel, top
and right panels). The tumours are surrounded by an inflammatory infiltrate (Inf).
The dark cells (arrows) correspond to melanophages (macrophages with pha-
gocytosed melanoma-derived melanin). The bottom sections from a metastatic
melanoma were not counterstained with haematoxylin. The specificity of the
reaction was assayed by the preincubation of the antibody with the peptide
(10 mg ml - 1) used for immunization (bottom right). Scale bars, 20 mm each.
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Preparation and stimulation of Tcells. Isolation of splenocytes and enriched
human T cells and their stimulation with concanavalin A and PHAwere done as
described2,30.
Apoptosis and cell proliferation assays. Reduced cell proliferation or
apoptosis as a result of death receptor stimulation or overexpression was
measured using the Celltiter 96 AQ proliferation assay (Promega) and the cell
death detection ELISA (Boehringer Mannheim), respectively, as previously
described3.
Proteaseactivityassays. Flag fusion proteins of the caspase homology region
of FLIPL and FLICE were generated in bacteria using modified pQE16 (Qiagen)
bacterial expression vectors. Protease activity was determined on fluorogenic
substrates as described7.
Chromosomal localization. A sequence-tagged site11 (A008B37) correspond-
ing to FLIP maps to human chromosome 2 in the interval between the markers
D2S116–D2S307. On the cytogenetic map, this interval corresponds to 2q33.
Received 19 May; accepted 11 June 1997.
1. Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
2. Klas, C., Debatin, K. M., Jonker, R. R. & Krammer, P. H. Activation interferes with the APO-1 pathway
in mature human T cells. Int. Immunol. 5, 625–630 (1993).
3. Thome, M. et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death
receptors. Nature 386, 517–521 (1997).
4. Boldin, M. P. et al. A novel protein that interacts with the death domain of Fas/APO1 contains a
sequence motif related to the death domain. J. Biol. Chem. 270, 7795–7798 (1995).
5. Chinnaiyan, A. M., O’Rourke, K., Tewari, M. & Dixit, V. M. FADD, a novel death domain-containing
protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505–512 (1995).
6. Muzio, M. et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the
CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817–827 (1996).
7. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. & Wallach, D. Involvement of MACH, a novel MORT1/
FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85, 803–815
(1996).
8. Bertin, J. et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-
and TNFR1-induced apoptosis. Proc. Natl Acad. Sci. USA 94, 1172–1176 (1997).
9. Bucher, P., Karplus, K., Moeri, N. & Hofmann, K. A flexible search technique based on generalized
profiles. Comput. Chem. 20, 3–24 (1996).
10. Fernandes-Alnemri, T. et al. In vitro activation of CPP32 and Mch3 by Mch4, a novel human
apoptotic cysteine protease containing two FADD-like domains. Proc. Natl Acad. Sci. USA 93, 7464–
7469 (1996).
11. Schuler, G. D. et al. A gene map of the human genome. Science 274, 540–546 (1996).
12. Walker, N. P. C. et al. Crystal structure of the cysteine protease interleukin-1-b-converting enzyme—a
(p20/p10)(2) homodimer. Cell 78, 343–352 (1994).
13. Wilson, K. P. et al. Structure and mechanism of interleukin-1b converting enzyme. Nature 370, 270–
275 (1994).
14. Vincenz, C. & Dixit, V. M. Fas-associated death domain protein interleukin-1b-converting enzyme 2
(FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death
signaling. J. Biol. Chem. 272, 6578–6583 (1997).
15. Kischkel, F. C. et al. Cytotoxicity-dependent Apo-1 (Fas/CD95)-associated proteins form a death-
inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579–5588 (1995).
16. Gu, Y. et al. Interleukin-1b converting enzyme requires oligomerization for activity of processed
forms in vivo. EMBO J. 14, 1923–1931 (1995).
17. Medema, J. P. et al. FLICE is activated by association with the CD95 death-inducing signaling complex
(DISC). EMBO J. 16, 2794–2804 (1997).
18. Bump, N. J. et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science
269, 1885–1888 (1995).
19. Xue, D. & Horvitz, H. R. Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-
3 cleavage site in baculovirus p35 protein. Nature 377, 248–251 (1995).
20. Bodmer, J. L. et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor
necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 6, 79–88 (1997).
21. Marsters, S. A. et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a
death domain and activates apoptosis and NF-kB. Curr. Biol. 6, 1669–1676 (1996).
22. Kitson, J. et al. A death-domain-containing receptor that mediates apoptosis. Nature 384, 372–375
(1996).
23. Yu, G. L. et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1
and CD95. Science 274, 990–992 (1996).
24. Tartaglia, L. A., Rothe, M., Hu, Y. F. & Goeddel, D. V. Tumor necrosis factor’s cytotoxic activity is
signaled by the p55 TNF receptor. Cell 73, 213–216 (1993).
25. Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113 (1997).
26. Peter, M. E. et al. Resistance of cultured peripheral T cells towards activation-induced cell death
involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling
complex. Eur. J. Immunol. 27, 1207–1212 (1997).
27. Hahne, M. et al. Melanoma cells express Fas(Apo-1/CD95) ligand: Implications for tumor immune
escape. Science 267, 1363–1366 (1996).
28. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449–1456 (1995).
29. Francis, M. J. et al. Immunological evaluation of the multiple antigen peptide (MAP) system using the
major immunogenic site of foot-and-mouth disease virus. Immunology 73, 249–254 (1991).
30. Lowin, B., Hahne, M., Mattmann, C. & Tschopp, J. Cytolytic T-cell cytoxocity is mediated through
perforin and Fas lytic pathways. Nature 370, 650–652 (1994).
Acknowledgements. We thank S. Belli for reading this manuscript; C. Servi for peptide synthesis; and
R. Bullani, S. Hertig, M. Rousseaux and T. Bornand for technical assistance. This work was supported by
grants of the Swiss National Science Foundation (J.T.) and the European Molecular Biology Organisation
(to M.T.).
Correspondence and requests for material should be addressed to J.T. (e-mail: jurg.tschopp@ib.unil.ch).
The Genbank accession numbers for FLIP cDNA sequences are U97074 (human FLIPL), U97075 (human
FLIPS), and U97076 (mouse FLIPL).
Tom5 functionally links
mitochondrial preprotein
receptors to thegeneral
import pore
Klaus Dietmeier*, Angelika Ho¨nlinger*, Ulf Bo¨mer,
Peter J. T. Dekker, Christoph Eckerskorn†,
Fritz Lottspeich†, Michael Ku¨brich & Nikolaus Pfanner
Institut fu¨r Biochemie und Molekularbiologie, Universita¨t Freiburg,
Hermann-Herder-Strasse 7, D-79104 Freiburg, Germany
† Max-Planck-Institut fu¨r Biochemie, D-82152 Martinsried, Germany
* These authors contributed equally to this study.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Most mitochondrial proteins are synthesized as preproteins on
cytosolic polysomes and are subsequently imported into the
organelle1–3. The mitochondrial outer membrane contains a
multisubunit preprotein translocase (Tom) which has receptors
on the cytosolic side and a general import pore (GIP) in the
membrane. Tom20–Tom22 and Tom70–Tom37 function as
import receptors4–7 with a preference for preproteins that have
amino-terminal presequences or internal targeting information,
respectively. Tom40 is an essential constituent of the GIP8,9,
whereas Tom6 and Tom7 modulate the assembly and dissociation
of the Tom machinery10,11. Here we report the identification of
Tom5, a small subunit that has a crucial role importing pre-
proteins destined for all four mitochondrial subcompartments.
Tom5 has a single membrane anchor and a cytosolic segment with
a negative net charge, and accepts preproteins from the receptors
and mediates their insertion into the GIP. We conclude that Tom5
represents a functional link between surface receptors and GIP,
and is part of an ‘acid chain’5 that guides the stepwise transport of
positively charged mitochondrial targeting sequences.
For the preparation of Tom machinery, digitonin-lysed mito-
chondria from the yeast Saccharomyces cerevisiae were subjected to a
coprecipitation with antibodies directed against Tom40. A non-
characterized band (labelled ‘Tom5’ in Fig. 1a, lane 2) was subjected
to N-terminal sequencing (Fig. 1b, sequence II). The sequence
matched to a previously unknown open reading frame (ORF) on
chromosome XVI (cosmid 9659, nucleotides 6,512–6,661), encod-
ing a 50-residue protein of relative molecular mass (Mr) 5.98K
(Fig. 1b) which we term Tom5. Its sequence does not reveal
significant homology to any known protein. The C-terminal half
of Tom5 contains a hydrophobic segment (residues 27–45) of
sufficient length to function as a membrane anchor. This segment
is flanked by positively charged residues that may interact with
negatively charged headgroups of membrane phospholipids. The
N-terminal portion of Tom5 carries a negative net charge (Fig. 1b).
Pure outer-membrane vesicles12,13 contained a prominent band
with an electrophoretic mobility like that of Tom5 (Fig. 1a, lane 1),
and N-terminal amino-acid sequencing confirmed that it was
indeed Tom5 (Fig. 1b, sequence I). An antiserum directed against
an N-terminal peptide of Tom5 was generated (Fig. 1a, lane 3). To
assess whether Tom5 is an integral membrane protein, mitochon-
dria were treated with sodium carbonate at pH 11.5 (ref. 11). This
treatment allows the extraction of soluble and peripheral membrane
proteins (Fig. 1c, columns 3 and 5) but leaves integral membrane
proteins in the membrane sheets (Fig. 1c, columns 2 and 4). Tom5
was fully resistant to extraction by sodium carbonate (Fig. 1c,
column 1), indicating that it is an integral membrane protein.
Tom5 was also resistant to treatment of mitochondria with trypsin
at all concentrations tested (Fig. 1d, lanes 2–6), even after lysis of the
mitochondria with Triton X-100 (Fig. 1d, lane 7). Treatment of
